Search results for "pooled analysis"

showing 10 items of 45 documents

Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: A pooled analysis

2017

Oncologymedicine.medical_specialtyPooled analysisOncologySite locationEgfr mutationbusiness.industryInternal medicinemedicineDiagnostic accuracyHematologybusinessAnnals of Oncology
researchProduct

51P Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)

2021

Oncologymedicine.medical_specialtySafety profilePooled analysisOncologybusiness.industryInternal medicinemedicineIn patientHematologybusinessIntrahepatic CholangiocarcinomaAnnals of Oncology
researchProduct

391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials

2021

Oncologymedicine.medical_specialtybusiness.industryColorectal cancerHematologymedicine.diseaseOutcome (game theory)Adjuvant TrialsMetforminPooled analysisOncologyInternal medicineDiabetes mellitusmedicinebusinessmedicine.drugAnnals of Oncology
researchProduct

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 …

2019

Introduction In MCL, progression-free survival (PFS) generally declines with each successive line of chemoimmunotherapy (CIT). We have previously published that with ibrutinib, a first-in-class oral inhibitor of Bruton's tyrosine kinase and a standard of care treatment (tx) for R/R MCL, median PFS exceeded 2 years (yrs) when used at first relapse (Rule S, et al. Haematologica. 2018;104:e211-e214). Here we present an updated pooled analysis with 15 months (mos) of additional follow-up, and for the first time, a comparison of outcomes with ibrutinib versus the prior regimen. Methods Patients (pts) enrolled in SPARK (MCL2001; NCT01599949), RAY (MCL3001; NCT01646021), and PCYC-1104 (NCT01236391…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologymedicine.diseaseBiochemistryCytokine release syndromechemistry.chemical_compoundRegimenPooled analysischemistryInternal medicineIbrutinibRelapsed refractoryLong term outcomesmedicineVindesineMantle cell lymphomabusinessmedicine.drugBlood
researchProduct

Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

2021

From 1985 to 2016, the prevalence of underweight decreased, and that of obesity and severe obesity increased, in most regions, with significant variation in the magnitude of these changes across regions. We investigated how much change in mean body mass index (BMI) explains changes in the prevalence of underweight, obesity, and severe obesity in different regions using data from 2896 population-based studies with 187 million participants. Changes in the prevalence of underweight and total obesity, and to a lesser extent severe obesity, are largely driven by shifts in the distribution of BMI, with smaller contributions from changes in the shape of the distribution. In East and Southeast Asia…

Population -- Health aspectsLeannessBaixo peso/UnderweightnoneDouble burdenalipainoisuustulotasoglobal healthsystematic analysisSedentary behaviorsRC1200Prospective associations0302 clinical medicineunderweightnälänhätäBiology (General)skin and connective tissue diseasesChildrenComputingMilieux_MISCELLANEOUSBody mass indexHuman Nutrition & Healtheducation.field_of_studyHumane Voeding & GezondheidylipainoGeneral Medicinekansainvälinen vertailu3. Good healthWorld healthMedicineA100 Pre-clinical MedicinePopulation distributionmedicine.medical_specialtyQH301-705.5ScienceSocio-culturaleNursing.Social sciencesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesThinnessSDG 3 - Good Health and Well-beingBMI; epidemiology; global health; none; obesity; underweightNoneHumansObesidade/ObesitySDG 2 - Zero HungereducationVLAGUS adultsOmvårdnadbody mass index; malnutrition; obesity underweightnutritional and metabolic diseasesmedicine.diseaseterveellisyysObesityFaculdade de Ciências SociaisBMI; epidemiology; global health; none; obesity; underweight; Body Mass Index; Humans; Obesity; Prevalence; Risk Factors; ThinnessGeneral BiochemistryWIASlihavuusunderweight ; obesity ; BMIBody mass indexRADemographyN.A.double burdenobesitySettore MED/09 - Medicina Internaalueelliset erotNutrition and DiseaseAnimal Nutrition[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematology0601 Biochemistry and Cell BiologyChange distribution of body mass indexRisk FactorsRA0421Voeding en ZiekteEpidemiologyPrevalenceMedicine and Health SciencesGlobal healthÍndice de massa corporal/Body Mass Index030212 general & internal medicineUnderweightpainoindeksi2. Zero hungerGeneral NeuroscienceQRaliravitsemuselintarvikkeethealthPublic Health Global Health Social Medicine and EpidemiologyDiervoeding3142 Public health care science environmental and occupational health//purl.org/pe-repo/ocde/ford#3.01.03 [https]/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingChinese adultsepidemiologypooled analysisUnderweightmedicine.symptomDiet qualityB120 PhysiologyResearch Articletrends//purl.org/pe-repo/ocde/ford#1.06.03 [https]prevalencePopulationMothersGenetics and Molecular Biologybody mass indexmalnutrition3121 Internal medicineBMImedicineLife Scienceddc:6103125 Otorhinolaryngology ophthalmologyObesitykehonkoostumusNutritionAustralian adultsGeneral Immunology and Microbiology//purl.org/pe-repo/ocde/ford#3.01.04 [https]Ciências sociaisFolkhälsovetenskap global hälsa socialmedicin och epidemiologiMalnutritionEpidemiology and Global Healthsense organsEstilos de Vida e Impacto na Saúde
researchProduct

167P Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer (aNSCLC): A pooled analysis of 6 randomized trials

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industryNeutropeniamedicine.diseaseTreatment efficacylaw.inventionPooled analysisOncologyRandomized controlled trialChemotherapy inducedlawInternal medicinemedicineNon small cellLung cancerbusinessJournal of Thoracic Oncology
researchProduct

Procedural characteristics and outcomes following chronic total occlusion coronary intervention: pooled analysis from 5 registries.

2021

Background Recent improvement in clinical skills, technology and hardware has resulted in improved success rates with chronic total occlusion (CTO) percutaneous coronary intervention (PCI). We performed a study level pooled analysis from the five largest registries of percutaneous coronary intervention (PCI) of CTO. Research design and methods We conducted pooled analysis of 9500 patients in registries and data on procedural characteristics, technical success, and MACCE was collected. Results A total of 9500 patients were included in the analysis. Mean age was 65.4 years with previous CABG in 24.8%, reattempt procedure in 24.8% and mean JCTO score was 2.2. Final wiring strategy in hybrid al…

Research designmedicine.medical_specialtymedicine.medical_treatmentCoronary AngiographyTotal occlusionPercutaneous Coronary InterventionRisk FactorsCardiac tamponadeInternal medicineInternal MedicineMedicineHumansRegistriesStrokeAgedbusiness.industryPercutaneous coronary interventionGeneral Medicinemedicine.diseasePooled analysisTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseCardiology and Cardiovascular MedicinebusinessComplicationExpert review of cardiovascular therapy
researchProduct

Benefits of tiotropium/olodaterol compared with tiotropium in patients receiving COPD LAMA at baseline: pooled analysis of 4 clinical trials

2020

medicine.medical_specialtyCOPDbiologybusiness.industryTiotropium-olodaterolLamabiology.organism_classificationmedicine.diseaseClinical trialPooled analysisInternal medicinemedicineIn patientbusinessBaseline (configuration management)61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
researchProduct

Improvement of asymmetric thyroid eye disease with teprotumumab

2021

PurposeTeprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye disease (TED) in recent clinical trials. Given its specificity, we expect it to demonstrate greater efficacy on the worse affected orbit, in patients with asymmetric TED. Herein, we investigate the differential impact of teprotumumab on the orbits of such patients.MethodsIn this pooled analysis of patients who were enrolled in the recent phase 2 (NCT01868997) and phase 3 (NCT03298867) trials, all patients with asymmetric TED (difference in exophthalmometry of ≥3 mm) were screened for eligibility. The primary outcomes of the trials, prop…

medicine.medical_specialtyEye disease030209 endocrinology & metabolismAntibodies Monoclonal HumanizedPlacebo03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineInternal medicineBlocking antibodyDiplopiamedicineExophthalmosHumansDifferential impactDiplopiabusiness.industryThyroidmedicine.diseaseeye diseasesSensory SystemsGraves OphthalmopathyClinical trialOphthalmologyPooled analysismedicine.anatomical_structure030221 ophthalmology & optometrymedicine.symptombusinessBritish Journal of Ophthalmology
researchProduct

The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Prot…

2021

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents, and it is also a potentially painful and debilitating condition. To date, no specific studies have prospectively evaluated the efficacy of its treatment and no robust standard of care has been established. Therefore, a systematic review (2007–2020) with a pooled analysis was performed in order to compare MRONJ surgical techniques (conservative or aggressive) versus combined surgical procedures (surgery plus a non-invasive procedure), where 1137 patients were included in the pooled analysis. A statistically significant difference in the 6-month improvement rate, comp…

medicine.medical_specialtyHealth Toxicology and Mutagenesismedicine.medical_treatmentONJReviewsurgerymedicineHumansAdverse effectONJ Osteonecrosis Staging Surgery Therapy TreatmenttherapyONJ; Osteonecrosis; Staging; Surgery; Therapy; Treatment; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Humans; Bone Density Conservation AgentsDiphosphonatesBone Density Conservation Agentstreatmentbusiness.industryosteonecrosisSignificant differenceBlood componentRPublic Health Environmental and Occupational HealthstagingSurgical proceduresmedicine.diseaseSurgeryPooled analysisImprovement rateMedicineBisphosphonate-Associated Osteonecrosis of the JawOsteonecrosis of the jawbusinessAdjuvantInternational Journal of Environmental Research and Public Health
researchProduct